Day: March 5, 2026

In pharmaceutical development, regulatory exclusivity can create a powerful competitive moat—often determining whether an innovative lifecycle strategy translates into meaningful market differentiation. The U.S. Food and Drug Administration (FDA) has released a draft guidance providing long-awaited clarity on the statutory and regulatory framework governing three-year exclusivity under the Hatch-Waxman Amendments. For regulatory affairs leaders, portfolio … Read more

Real-world data (RWD) has transitioned from an exploratory research asset to a strategic regulatory tool shaping post-market drug safety evaluations. As healthcare systems generate increasingly complex datasets, from electronic health records to insurance claims and disease registries, regulators are demanding more rigorous frameworks for translating these data into regulatory-grade evidence. The FDA’s adoption of the … Read more